Supplementary Online Content Whiting PF, Wolff RF, Deshpande S, et a. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. doi: 10.1001/jama.2015.6358 This supplementary material has been provided by the authors to give readers additional information about their work. © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 Table of Contents eAppendix 1. Review Protocol ........................................................................................................ 4 eAppendix 2. Search Strategy ......................................................................................................... 5 DATABASES SEARCHED: .................................................................................................................. 5 EMBASE SEARCH STRATEGY ........................................................................................................... 6 eAppendix 3. Nausea and Vomiting Due to Chemotherapy ........................................................... 7 A. STUDY CHARACTERISTICS..................................................................................................... 7 B. DICHOTOMOUS OUTCOME RESULTS ................................................................................. 11 C. CONTINUOUS OUTCOME RESULTS .................................................................................... 12 D. CATEGORICAL OUTCOME RESULTS ................................................................................... 15 E. CROSS-OVER TRIALS THAT COMPARED TREATMENTS WITHIN PATIENTS ......................... 17 eAppendix 4. Appetite Stimulation in HIV/AIDS ........................................................................... 18 A. STUDY CHARACTERISTICS .................................................................................................. 18 B. DICHOTOMOUS OUTCOME RESULTS ................................................................................. 19 C. CONTINUOUS OUTCOME RESULTS .................................................................................... 19 eAppendix 5. Chronic Pain ............................................................................................................ 20 A: STUDY CHARACTERISTICS .................................................................................................. 20 B. DICHOTOMOUS OUTCOME RESULTS ................................................................................. 25 C. CONTINUOUS OUTCOME RESULTS .................................................................................... 26 eAppendix 6. Spasticity in MS and Paraplegia .............................................................................. 36 A. STUDY CHARACTERISTICS................................................................................................... 36 B. DICHOTOMOUS OUTCOMES RESULTS .............................................................................. 38 C. CONTINUOUS OUTCOME RESULTS .................................................................................... 38 eAppendix 7. Depression .............................................................................................................. 43 A. CONTINUOUS OUTCOME MEASURES ............................................................................... 43 eAppendix 8. Anxiety Disorder ..................................................................................................... 44 A. STUDY CHARACTERISTICS................................................................................................... 44 B. CONTINUOUS OUTCOME RESULTS .................................................................................... 45 eAppendix 9. Sleep Disorder ......................................................................................................... 46 A. STUDY CHARACTERISTICS................................................................................................... 46 B. DICHOTOMOUS OUTCOMES RESULTS .............................................................................. 47 C. CONTINUOUS OUTCOMES RESULTS .................................................................................. 47 eAppendix 10. Psychosis ............................................................................................................... 50 A. STUDY CHARACTERISTICS................................................................................................... 50 B. CONTINUOUS OUTCOMES RESULTS .................................................................................. 51 eAppendix 11. Glaucoma .............................................................................................................. 52 A. STUDY CHARACTERISTICS................................................................................................... 52 B. CONTINUOUS OUTCOMES RESULTS .................................................................................. 53 © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eAppendix 12. Tourette Syndrome ............................................................................................... 54 A. STUDY CHARACTERISTICS .................................................................................................. 54 B. CONTINUOUS OUTCOMES RESULTS .................................................................................. 55 eAppendices 13. Risk of Bias in Each Included Study, Grouped by Indication ............................. 56 eReferences. ................................................................................................................................. 59 © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eAppendix 1. Review Protocol See separate pdf document © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eAppendix 2. Search Strategy Databases searched: • Cochrane Database of Systematic Reviews (CDSR) (Wiley): Issue 4/12, April 2015 • Database of Abstracts of Reviews of Effects (DARE) (Wiley): Issue 1/4, January 2015 • Health Technology Assessment Database (HTA) (Wiley): Issue 1/4, January 2015 • NHS Economic Evaluation Database (NHS EED) (Wiley): Issue 1/4, January 2015 • International Network of Agencies for Health Technology Assessment (INAHTA) (Internet): up to 2015/4/9 • National Institute for Health Research (NIHR) Project Portfolio (Internet): up to 2015/4/9 • International Guidelines Library (GIN) (Internet): 2000-2015/4/9 • National Guidelines Clearinghouse (NGC) (Internet): up to 2015/4/9 • National Institute for Health and Care Excellence (NICE) Guidance (Internet): up to 2015/4/9 • Turning Evidence into Practice (TRIP) database (Internet): up to 2015/4/9 • Canadian Agency for Drugs and Technologies in Health (CADTH) (Internet): up to 2015/4/9 • PROSPERO (Internet): up to 9/4/2015 • International Information Network on New and Emerging Health Technologies (EuroScan) (Internet): up to 2015/4/9 • Embase (OvidSP): 1974-2015/wk 14 • Medline (OvidSP): 1946-2015/Mar wk 5 • Medline In-Process & Daily Update (OvidSP): up to 7 April 2015 • PubMed (https://www.ncbi.nlm.nih.gov/pubmed): up to 8.4.2015 • PsycINFO (OvidSP): 1806-2015/Mar wk 5 • BIOSIS Citation Index (Web of Knowledge): 1926-2015/04/07 • CINAHL (Cumulative Index to Nursing and Allied Health Literature) (EBSCO): 1981-2015/04/03 • Science Citation Index (Web of Knowledge): 1900-2015/04/08 • Allied and Complimentary Medicine Database (AMED) (ProQuest): 1985-2015 (Current) • Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley): Issue 3/12, March 2015 • International Association of Cannabis Medicines (IACM) (Internet): up to 2015/04/09 • IACM Database of Clinical Studies and Case Reports (Internet): up to 2015/04/09 • National Institutes of Health (NIH) Clinicaltrials.gov (Internet): up to 2015/4/9 • metaRegister of Controlled Trials (mRCT) (Internet): up to 2014/4/7 • World Health Organization (WHO) International Clinical Trials Register Portfolio (ICTRP) (Internet): up to 9/04/15 Databases highlighted in grey are grey literature sources © 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 EMBASE search strategy Embase (OvidSP): 1974-2015/wk 14; Searched 8.4.15 1 Cannabaceae/ (57) 2 exp cannabinoid/ (46319) 3 (marijuana or marihuana or cannabis or canabis).ti,ab,ot,hw. (34580) 4 (Hashish or hash or bhang or ganja or ganjah or hemp or charas).ti,ab,ot,hw. (1814) 5 (cannador or eucannabinolide or 8001-45-4 or 8063-14-7 or 38458-58-1).ti,ab,ot,hw,rn. (22203) 6 (9tetrahydrocannabinol$ or delta3-thc or sp-104 or sp104 or 1972-08-3).ti,ab,ot,hw,rn. (4927) 7 (Dronabinol or Marinol or dronabinolum or deltanyne or ea-1477 or ea1477 or tetranabinex or qcd-84924 or qcd84924 or 7663-50-5).ti,ab,ot,hw,rn. (5801) 8 (delta-9-THC or 5957-75-5 or 1972-08-3).ti,ab,ot,hw,rn. (5302) 9 delta9?11?tetrahydrocannabinol.ti,ab,ot,hw. (0) 10 (THC or CBD or AEA).ti,ab,ot. (14442) 11 (nabidiolex or 13956-29-1).ti,ab,ot,hw,rn. (2003) 12 (dexanabinol or Hu-210 or Hu-211 or hu210 or hu211 or 112924-45-5).ti,ab,ot,hw,rn. (1126) 13 (Cannabichromene or 521-35-7).ti,ab,ot,hw,rn. (983) 14 (Nabilone or Cesamet or cesametic or cpd109514 or cpd-109514 or lilly-109514 or lilly109514 or 51022-71- 0).ti,ab,ot,hw,rn. (1012) 15 (Nabiximols or Sativex or Gw-1000 or gw1000 or sab-378 or sab378 or 56575-23-6).ti,ab,ot,hw,rn.